🟢 CLPT is trading 5.8% up today as Huntington’s gene therapy data fuels extended rally

CLPT is trading at $18.05 (5.8% up), extending a sharp rally triggered by positive three-year Phase I/II data for the AMT-130 Huntington’s disease gene therapy from partner uniQure.

• The trial results highlighted the critical role of CLPT's neurosurgical platform in the delivery and success of the gene therapy program.
• The stock's upward move persists despite broader market weakness, suggesting investors are repricing the company's strategic value in Huntington’s and other gene therapy applications.